Modulated electrohyperthermia in locally advanced cervical cancer Results of an observational study of 95 patients
방 식 : CT+RT+mEHT
암종류 : Cervical cancer
연 도 : 2023
저 자 : Sun Young Lee, Dong Hyun Lee, Dong-Hyu Cho.
[Abstract]
Most federation of gynecology and obstetrics stage II or higher locally advanced cervical cancer (LACC) patients are treated with
concurrent chemoradiotherapy (CCRT); however, recurrence is high, and the prognosis is poor. In this observational retrospective
study, data from LACC patients treated with CCRT alone or combined with modulated electrohyperthermia (mEHT) were collected
from 2011 to 2018. Ninety-five LACC patients, including 53 (%) treated with CCRT alone and 42 (%) treated with CCRT + mEHT,
were enrolled. The complete remission rate significantly increased with CCRT + mEHT compared with CCRT alone among LACC
cases with lymph node metastasis (45% vs 71%, P = .0377). Additionally, at the last follow-up point, the no-evidence-of-disease
rate significantly improved with CCRT + mEHT compared with CCRT (58% vs 82%, P = .0315). Disease-free survival increased
in the CCRT + mEHT group with lymph node metastasis (P = .04). The addition of mEHT to CCRT led to a better therapeutic
response in LACC with regional lymph node metastasis without severe complications.
Most federation of gynecology and obstetrics stage II or higher locally advanced cervical cancer (LACC) patients are treated with
concurrent chemoradiotherapy (CCRT); however, recurrence is high, and the prognosis is poor. In this observational retrospective
study, data from LACC patients treated with CCRT alone or combined with modulated electrohyperthermia (mEHT) were collected
from 2011 to 2018. Ninety-five LACC patients, including 53 (%) treated with CCRT alone and 42 (%) treated with CCRT + mEHT,
were enrolled. The complete remission rate significantly increased with CCRT + mEHT compared with CCRT alone among LACC
cases with lymph node metastasis (45% vs 71%, P = .0377). Additionally, at the last follow-up point, the no-evidence-of-disease
rate significantly improved with CCRT + mEHT compared with CCRT (58% vs 82%, P = .0315). Disease-free survival increased
in the CCRT + mEHT group with lymph node metastasis (P = .04). The addition of mEHT to CCRT led to a better therapeutic
response in LACC with regional lymph node metastasis without severe complications.
